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ment (SCI), amnestic mild cognitive impairment (MCI) and 
non-amnestic MCI.  Methods: Data from 16 centers across Eu-
rope were analyzed.  Results: A north-south gradient in  APOE 
  4 prevalence existed in the total sample (62.7% for  APOE   4 
carriers in the northern region, 42.1% in the middle region, 
and 31.5% in the southern region) and in subjects with SCI 
and amnestic MCI separately. Only in Middle Europe was the 
 APOE   4 allele significantly associated with poor perfor-
mance on tests of delayed recall and learning, as well as with 
the amnestic subtype of MCI.  Conclusion: The  APOE   4 allele 
frequencies in subjects with SCI and amnestic MCI have a 
north-south gradient. The relation between the  APOE   4 al-
lele and cognition is region dependent. 
 Copyright © 2011 S. Karger AG, Basel 
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 Abstract 
 Background: The  APOE   4 allele is a risk factor for Alzhei-
mer’s disease (AD).  APOE   4 is common in non-demented 
subjects with cognitive impairment. In both healthy people 
and people with AD, its prevalence has a north-south gradi-
ent across Europe. In the present study, we investigated 
whether the relation between the  APOE   4 allele and cogni-
tive impairment varied across Northern, Middle and South-
ern Europe. We also investigated whether a north-south gra-
dient existed in subjects with subjective cognitive impair-
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 Introduction 
 The   4 allele of the apolipoprotein E gene  ( APOE   4) 
is one of the most important and well-replicated genetic 
risk factors for Alzheimer disease (AD)  [1] . Studies have 
also linked the  APOE   4 allele to subjective cognitive im-
pairment (SCI) and mild cognitive impairment (MCI)  [2, 
3] . MCI refers to subjects with cognitive impairment 
worse than what would be expected relative to their age, 
but where the impairment is not severe enough to fulfill 
the diagnostic criteria of dementia  [4, 5] . Subjects with 
SCI have cognitive complaints, but do not show impair-
ments on cognitive testing  [3] .
 The prevalence of the  APOE   4 allele varies greatly in 
different populations. In Europe, a north-south gradient 
has been observed in healthy subjects but also in subjects 
with AD  [6] . The frequency of the   4 allele is highest in the 
north and lowest in the south  [6–10] ( table 1 ). It is not clear 
whether such a gradient also exists in subjects with SCI and 
MCI. Further, it is possible that the  APOE   4 allele contrib-
utes differently to cognitive impairment across geographi-
cal regions, but this has not yet been investigated. 
 The aim of this study was to investigate whether a 
north-south gradient exists for the prevalence of the 
 APOE   4 allele in subjects with SCI and MCI. Further, we 
investigated the association between the  APOE   4 allele 
and neuropsychological test performance, as well as with 
SCI and the amnestic and non-amnestic subgroups of 
MCI, in Northern, Middle and Southern Europe sepa-
rately. Because previous research has shown that  APOE 
  4 interacts with age  [11, 12] and gender  [13] in cognitive 
decline, we also investigated the impact of these demo-
graphic factors on cognition. 
 Methods 
 Study Sample 
 Subjects were selected from the DESCRIPA study, a European 
multicenter study with the goal of developing screening guide-
lines and clinical criteria for patients with pre-dementia AD  [14] . 
Inclusion criteria were: consecutive referral to a memory clinic 
and age 55 years or older. Exclusion criteria were: previous clinical 
evaluation, no symptoms, dementia at baseline according to ICD-
10 (2 centers) or DSM-IV (14 centers) criteria, and cognitive im-
pairment due to known somatic, psychiatric or neurological dis-
orders (e.g. brain infection, epilepsy that was currently being 
treated, and severe depression). The study closely followed regular 
clinical practice or was performed as part of a research project. 
All subjects had consented to participation in the study, and it was 
approved by the local medical ethics committee in each centre.
 For the present analyses, we selected subjects from 16 centers 
where blood for  APOE genotyping had been collected (n = 696). 
Subjects whose  APOE status was unknown (n = 128) or could not 
be classified into a diagnostic group because of missing data on 
neuropsychological tests (n = 48) were excluded. The final sam-
ple consisted of 520 subjects (59% female). The 16 centers were 
subdivided into three regions (according to  [10] ): North (n = 83): 
Huddinge and Malmö (Sweden), Kuopio (Finland); Middle (n = 
202): Maastricht, Nijmegen and Amsterdam (The Netherlands), 
Paris (France), Bristol, Bath (England), Mannheim and Munich 
(Germany); and South (n = 235): Toulouse (France), Thessalo-
niki (Greece), Genoa and Brescia (Italy), and Bucharest (Roma-
nia).
 Excluded subjects were compared to included subjects in 
terms of demographic variables (age, gender, and education), 
Mini-Mental State Examination (MMSE) and neuropsychologi-
cal tests (delayed recall, learning, trail making test A and B, lan-
guage, and visuoconstruction). This was done separately for the 
three regions. In the northern region, excluded subjects had bet-
ter performance than those retained in the study on the MMSE 
[F(d.f. = 1) = 4.588, p = 0.035] and delayed recall [F(d.f. = 1) = 5.20, 
p = 0.021]. In the southern region, excluded subjects had more 
years of education than those retained in the study [F(d.f. = 1) = 
5.197, p = 0.023]. There was also a significant difference in the 
percentage of missing data across regions (p = 0.001): the southern 
region had 36.6% missing data, the middle region had 18.8%, and 
the northern region had 23.5%. 
 Baseline Clinical Assessment 
 Standard procedure at all centers for baseline clinical assess-
ment included physical examination, laboratory assessment, 
blood, and – where feasible – CSF sampling, as well as clinical 
evaluation using the MMSE  [15] , the Clinical Dementia Rating 
Scale  [16] or the Global Deterioration Scale  [17] . These procedures 
have been described in more detail elsewhere  [14] .
 Neuropsychological Assessment  
 There was a battery of neuropsychological tests performed on 
all subjects in order to assess performance in the cognitive do-
mains of memory, language, executive function and attention, 
and visuospatial function. As the DESCRIPA study followed rou-
tine clinical practice in each center, the tests used to assess each 
domain sometimes varied between centers. For that reason, a pri-
mary neuropsychological test for each cognitive domain was cho-
sen in all centers that was identical or similar to tests used in 
other centers  [14] . Raw scores were converted to age-, education-, 
and gender-corrected z-scores according to locally collected nor-
mative data or published normative data, and these z-scores were 
used for further analyses. The tests used were as follows:
 Verbal Memory . Immediate or delayed recall from the Rey Au-
ditory Verbal Learning Test  [18] (8 centers), the word list of the 
Consortium to Establish a Registry for AD (CERAD) neuropsycho-
logical battery  [19] (3 centers), the Grober-Buschke Test  [20] (1 cen-
ter), the Selective Reminding Test  [21] (1 center), the Alz heimer’s 
Disease Assessment Scale-cognitive subscale, 10 word list  [22] (1 
center), or the Hopkins Verbal Learning Test  [23] (2 centers).
 Language . Verbal Fluency Test, using either animals for 1 min 
 [24] (15 centers) or 1 min for cars, fruits, and animals  [25] (1 center).
 Visuospatial Function . The Rey-Osterrieth Figure Copy Test 
 [26] (10 centers), the copy figures part from the Mental Deteriora-
tion Battery  [27] (1 center), the figures part from CERAD  [19] (3 
centers), the cube analysis test of the Visual Object and Space Per-
 Regional Differences in Effects of  APOE 
  4 
Dement Geriatr Cogn Disord 2011;32:135–142 137
ception Battery  [28] (1 center), or the copy figure item of the 
MMSE (1 center) using a score of 0 as indicative of impairment.
 Executive Function . The Trail Making Test A and B  [29] (15 
centers) or the attention item of the MMSE (1 center) using a score 
of 1 or lower as indicative of impairment. 
 Definition of SCI and MCI 
 Subjects were classified centrally into three subgroups based 
on performance on the neuropsychological tests. The classifica-
tion was made independently of other variables, including the 
 APOE genotype. Impairment was defined as age-, gender- and 
education-corrected z-score below –1.5, unless specified other-
wise. Subjects without psychometric impairment on any of the 
primary tests were classified as SCI (n = 130). Subjective com-
plaints were considered to be present as these subjects had at-
tended the memory clinic because of perceived cognitive impair-
ments. Subjects with impairment on the learning subtask or de-
layed recall subtask of the word-list learning tasks were classified 
as amnestic MCI (n = 256). Subjects with impairment on any of 
the other tests other than memory (i.e. fluency, visuospatial func-
tion, attention) were classified as non-amnestic MCI (n = 134). 
 Genotyping  
 APOE genotypes were determined on genomic DNA extracted 
from EDTA blood using the SNaPshot technique  [30] . 
 Statistical Analysis 
 SPSS 16.0 for Windows was used for statistical analyses (  = 
0.05). Differences between subjects with or without missing data 
were analyzed using ANOVA or Pearson’s   2 test. Also, differ-
ences between diagnostic groups (SCI, amnestic MCI and non-
amnestic MCI) in demographic variables (age, gender, and educa-
tion) were analyzed with ANOVA or Pearson’s   2 test. Post hoc 
analyses were done using Scheffé and logistic regression. Hardy-
Weinberg equilibrium was tested in the  APOE genotype, also by 
using Pearson’s   2 test. 
The cognitive profiles of  APOE   4 carriers (one or two   4 al-
leles) were compared to   APOE -  4 -negative subjects (no  APOE   4 
alleles). This was done with both t-tests and ANCOVA (with age 
and education as covariates), which provided similar results. Out-
liers (defined as any score 83.29 SD, p   ! 0.001 two-tailed test, of 
each subgroup or regional mean) were excluded, resulting in 0.3% 
data loss.
 Differences in  APOE   4 genotypes (presence of at least one 
 APOE   4 allele) between diagnostic groups were analyzed with 
multinomial logistic regression, by using clinical subgroup (SCI 
as reference, non-amnestic MCI, and amnestic MCI) as depen-
dent variables, and controlling for age, gender and education. 
This was done in the total sample and in each region separately. 
Interactions could not be included since this gave rise to singu-
larities in the Hessian matrix. 
 Binary logistic regression was used for pairwise comparisons 
(amnestic MCI vs. SCI, amnestic MCI vs. non-amnestic MCI and 
non-amnestic MCI vs. SCI). Demographic variables (age, educa-
tion and gender) were entered in the first step, the  APOE   4 vari-
able in the second step, and interactions for the presence of  APOE 
  4 with age and gender in the third step. Because both main ef-
fects and interaction effects of age were studied, this variable was 
centered in order to avoid multicolinearity.
 Results  
 The distribution of  APOE genotypes was in Hardy-
Weinberg equilibrium in the total material as well as in 
the diagnostic subgroups, indicating a stable relationship 
between the different alleles (Hardy-Weinberg equilibri-
um test p  1 0.05).
 Demographic characteristics (age, gender and educa-
tion), MMSE scores and  APOE genotype data in the total 
group and in the diagnostic categories of SCI, non-amnes-
tic MCI and amnestic MCI in each region are shown in 
 tables 2 and  3 . In the total sample, we noted differences in 
Table 1.  North-south gradient in APOE 4 frequency across Europe in population-based studies (%)
Study Subjects North1 Middle2 South3
APOE 4 carriers
Schiele et al. [9] middle-aged subjects 25–65 years 33 25 20
Tiret et al. [8] young subjects (18–26 years)
with family history of myocardial infarction 29 25 21
Panza et al. [6] middle-aged subjects 42 20 15
centenarians 17 11 4.5
APOE 4 allele frequency
Corbo and Scacchi [10] population studies 20 14 9
1  Finland (n = 1,911) [9]; Sweden, Denmark, Northern Germany (n = 315) [8]; Finland (n = 170–207) [6]; Finland, Sweden, Norway, 
Iceland (n = 3,104) [10]. 
2 France, Ireland (n = 2,585) [9]; Belgium, Austria, Switzerland (n = 327) [8]; France (n = 161–325) [6]; Scotland, The Netherlands, 
Germany, France, Hungary, Austria, Switzerland (n = 6,821) [10]. 
3 Portugal, Greece, Spain (n = 1,979) [9]; Italy, Spain, Southern France (n = 311) [8], Italy (n = 67–311) [6]; Italy, Spain (n = 2,117) [10].
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age, education and gender between the regions (p = 0.001 
for all differences), but absolute differences were small. 
 In the total sample, the prevalence of  APOE   4 carriers 
was 40.0 % in SCI, 36.6% in non-amnestic MCI and 44.5% 
in amnestic MCI. These differences were not statistically 
significant [  2 (d.f. = 2, n = 520) = 2.430, p = 0.3]. There
was a significant difference in the frequency of  APOE   4 
carriers between regions [  2 (d.f. = 2, n = 520) = 25.010,
p = 0.001] and it showed a north-south gradient with a 
prevalence of 62.7% for  APOE   4 carriers in the northern 
region, 42.1% in the middle region, and 31.5% in the south-
ern region. Such a gradient also existed for subjects with 
SCI (p = 0.001) and subjects with amnestic MCI (p = 0.001), 
but not for subjects with non-amnestic MCI ( fig. 1 ). 
 The effect of  APOE   4 on test performance in each re-
gion is shown in  table 4 . In Middle Europe, the presence 
of the  APOE   4 allele was associated with worse perfor-
mance on learning [F(d.f. = 1) = 5.0, p = 0.03] and delayed 
Table 2.  Baseline characteristics according to diagnostic group
Total SCI naMCI aMCI p Post hoc
Northern Europe
n 83 36 18 29
Male/female 43/40 19/17 8/10 16/13 0.8
Age, years 67.287.0 65.687.0 66.385.3 69.687.5 0.06
Education, years 10.983.8 11.583.7 11.084.0 10.083.9 0.3
MMSE 27.382.6 28.481.6 27.682.0 25.783.2 0.001 aMCI<SCI, naMCI
Middle Europe
n 202 59 42 101
Male/female 95/107 29/30 28/14 38/63 0.006 aMCI>naMCI
Age, years 69.888.3 67.988.6 70.389.1 70.787.7 0.1
Education, years 11.383.7 12.584.2 11.183.8 10.783.3 0.01 aMCI<SCI
MMSE 27.282.2 28.481.5 27.681.8 26.482.4 0.001 aMCI<SCI, naMCI
Southern Europe
n 235 35 74 126
Male/female 76/159 12/23 17/57 47/79 0.2
Age, years 70.187.7 67.886.5 70.287.4 70.788.1 0.1
Education, years 8.984.5 9.484.1 7.784.2 9.484.7 0.03 aMCI>naMCI
MMSE 27.682.0 28.881.3 27.682.1 27.281.9 0.001 SCI>aMCI, naMCI
W here indicated, data are means 8 SD. 
Table 3.  APOE allele frequency across diagnostic groups
23 24 33 34 44 Total 2 Total 3 Total 4
Northern Europe
SCI 3 (8) 1 (3) 9 (25) 22 (61) 1 (3) 4 (6) 43 (60) 25 (35)
naMCI 0 0 9 (50) 9 (50) 0 0 27 (75) 9 (25)
aMCI 0 3 (10) 10 (35) 12 (41) 4 (14) 3 (5) 32 (55) 23 (40)
Middle Europe
SCI 4 (7) 2 (3) 37 (63) 14 (24) 2 (3) 6 (5) 92 (78) 20 (17)
naMCI 3 (7) 1 (2) 25 (60) 11 (26) 2 (5) 4 (5) 64 (76) 16 (19)
aMCI 10 (10) 3 (3) 38 (38) 36 (36) 14 (14) 13 (6) 122 (60) 67 (33)
Southern Europe
SCI 3 (9) 1 (3) 25 (71) 6 (17) 0 4 (6) 59 (84) 7 (10)
naMCI 6 (8) 2 (3) 42 (57) 20 (27) 4 (5) 8 (5) 110 (74) 30 (20)
aMCI 8 (6) 0 77 (61) 36 (29) 5 (4) 8 (3) 198 (79) 46 (19)
D ata are n (%) for each genotype. 
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recall [F(d.f. = 1) = 20.3, p = 0.001]. In Northern Europe, 
there was also a tendency for  APOE   4 carriers to per-
form better on tests of visuospatial function  than non-
carriers [F(d.f. = 1) = 3.5, p = 0.07]. There was no signifi-
cant effect of  APOE   4 on neuropsychological test perfor-
mance in Southern Europe. 
 The same pattern also held for categorical data. The 
multinomial logistic regression showed that in the total 
sample,  APOE   4 was not associated with diagnostic 
group. When multinomial logistic regression was done 
separately for the three regions, the frequency of  APOE 
  4 carriers differed between diagnostic groups in Middle 
Europe only [likelihood ratio test:   2 (d.f. = 8, n = 202) = 
32.88, p = 0.001], explaining 17.2% of the variance in 
group membership (Nagelkerke’s R 2 ). Pair-wise compar-
isons showed that  APOE   4 carriers were more common 
in amnestic MCI than in non-amnestic MCI (OR = 2.4, 
95% CI = 1.1–5.2, p = 0.032) or in SCI (OR = 2.9, 95% CI 
1.42–6.1, p = 0.004). In this region, age interacted with 
 APOE   4 in the comparison between non-amnestic MCI 
and SCI (OR = 1.1, 95% CI 1.0–1.3, p = 0.043), indicating 
that the likelihood for  APOE   4 carriers of being in the 
non-amnestic MCI subgroup compared to the SCI sub-
group increased with age.
 Discussion  
 The present study provides evidence for regional ef-
fects of  APOE   4 on cognitive function. Results show 
that there was an association between  APOE   4 and poor 
performance on tests of learning and delayed recall only 
in Middle Europe, where  APOE   4 also was associated 
with amnestic MCI. Further,  APOE   4 interacted with 
old age in this region to predict non-amnestic MCI. In 
the northern region, there was a trend for  APOE   4 car-
riers to be associated with improved performance on 
tests of visuospatial function. There was also a north-
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 Fig. 1.  APOE   4 carriers (%) according to diagnosis and region 
(North, Middle and South Europe). Data for controls are taken 
from Schiele et al.  [9] and used for comparison purposes only. 
Table 4.  Relation between APOE 4 carriers and neuropsychological test data across regions
Northern Europe Middle Europe S outhern Europe
n no 4 4 carrier p n no 4 4 carrier p n no 4 4 carrier p
Language
Fluency 78 –0.7 (1.2) –0.3 (1.1) 0.1 201 –0.7 (1.0) –0.7 (1.0) 0.9 234 –1.0 (1.0) –1.1 (0.9) 0.5
Executive functioning
TMT-A 81 –0.3 (1.5) 0.06 (1.0) 0.2 201 –0.6 (1.6) –0.5 (1.2) 0.9 198 –1.3 (1.8) –1.4 (1.7) 0.8
TMT-B 78 –0.09 (1.1) –0.2 (1.2) 0.7 197 –0.5 (1.8) –0.5 (1.6) 0.9 197 –1.9 (2.1) –1.7 (2.0) 0.6
Memory
Learning 83 –0.4 (1.3) –0.4 (1.4) 0.9 201 –0.9 (1.2) –1.3 (1.2) 0.03 234 –1.0 (1.2) –1.1 (1.1) 0.7
Delayed recall 82 –0.5 (1.3) –0.6 (1.4) 0.7 195 –0.8 (1.2) –1.7 (1.5) 0.001 235 –1.1 (1.2) –1.2 (1.3) 0.4
Visuospatial function 
Figure 79 0.1 (1.1) 0.6 (1.0) 0.07 179 0.04 (1.2) 0.2 (1.0) 0.5 228 0.06 (1.2) –0.05 (1.2) 0.6
Dat a are Z-scores (means and SD). TMT = Trail-Making Test.
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south gradient in the regional distribution of  APOE   4 
carriers.
 The association of  APOE   4 with amnestic MCI and 
poor performance on tests of learning and delayed recall 
is consistent with previous studies  [12, 31, 32] . However, 
this study shows that the association only holds for Mid-
dle Europe. Indeed, two of the previous studies investi-
gating this association only involved subjects from this 
region  [12, 31] . The study conducted by Farlow et al.  [32] 
used data from the InDDEx study, which includes pa-
tients from 14 different countries in Europe and North 
America  [33] , and therefore their results cannot be inter-
preted in terms of regional effects. 
 It could be the case that the observed association be-
tween  APOE   4 and poor cognitive performance is re-
lated to lifestyle.  APOE alleles have previously been found 
to modulate alcohol-mediated effects on LDL cholesterol 
 [34] , whilst  APOE   2 is thought to be associated with a 
stronger triacylglycerol response to high dietary sucrose 
intakes than seen in coronary artery disease patients with 
the  APOE   3  or   4  alleles  [35] . Both alcohol and dietary 
sucrose intake is likely to vary across the Middle Europe 
region which, when combined with suggested gender  [36] 
and geographical associations with  APOE variability  [6] , 
would certainly make this a complicated association, but 
one which is nonetheless possible and perhaps more pro-
nounced within Middle Europe. 
 In the northern region,  APOE   4 carriers tended to be 
associated with better performance on visuospatial func-
tion than subjects with no APOE   4. This was an unex-
pected result that, to our knowledge, has not been dem-
onstrated before and therefore needs to be replicated. 
 A remarkable finding was the high prevalence of 
 APOE   4 in subjects with SCI. Indeed, in the northern 
region the prevalence of  APOE   4 in SCI was just as high 
as in amnestic MCI, and much higher than expected for 
the region based on control data ( fig. 1 ). The association 
of SCI and neurodegeneration is disputed. Some studies 
indicate that SCI is not primarily linked to neurodegen-
eration, but rather to depression [e.g.  37 ] and personality 
[e.g.  38 ]. However, other studies have also found a high 
prevalence of  APOE   4 in SCI [e.g.  3, 39, 40 ]. A review of 
studies by Jonker et al.  [41] concluded that SCI should not 
be considered as being merely a symptom of depression, 
but rather as an early sign of dementia. Recent studies 
have also found that SCI is related to AD biomarkers, 
such as a smaller entorhinal cortex or hippocampal vol-
ume  [42, 43] or abnormal cerebrospinal fluid markers 
 [44] . In separate studies from the DESCRIPA project, SCI 
was associated with abnormal EEG, consistent with latent 
AD pathology  [45] and CSF markers suggestive of AD 
 [46] . Together, this implies an increased risk for AD in 
subjects with SCI. 
 The non-amnestic MCI subgroup is usually thought 
to have a heterogeneous etiology leading to various 
types of dementia, such as vascular dementia, fronto-
temporal dementia and dementia with Lewy bodies  [2] . 
The high prevalence in this study of  APOE   4 in the 
non-amnestic MCI subgroup implies increased risk for 
AD for subjects in this diagnostic group as well. Indeed, 
in a separate study from the DESCRIPA project, non-
amnestic MCI was associated with CSF markers sugges-
tive of AD  [46] . 
 Previous studies  [11, 12] have shown that the APOE   4 
allele interacts with age in affecting memory – meaning 
that increased age strengthens the negative impact of 
 APOE   4 on memory performance. In our study, it was 
shown that this interaction could predict non-amnestic 
MCI when contrasted with SCI in Middle Europe. This 
meant that in elderly subjects, those with an  APOE   4 al-
lele were more likely to develop impairment in domains 
other than memory, rather than just subjective com-
plaints. There was no interaction found with gender.
 Our study is the first to show a north-south gradient 
of  APOE   4 in MCI patients, possibly accelerating the 
onset of AD in these subjects. It extends findings from 
studies conducted in healthy controls and subjects with 
AD. In the analysis with the different diagnostic groups, 
a north-south gradient was present only for subjects 
with amnestic MCI and SCI. The lack of a gradient in 
subjects with non-amnestic MCI could be explained by 
the small sample size in this group, especially in the 
northern region. Further, it should be noted that even 
though the  APOE   4 allele was only associated with am-
nestic MCI in Middle Europe, the prevalence of the 
 APOE   4 allele carriers in subjects with amnestic MCI 
was increased in all regions relative to the control data 
in  figure 1 . 
 There were differences between centers in procedures, 
and there are for that reason a number of potential threats 
to the conclusions of the study that need to be addressed. 
First, the results could not have been influenced by dif-
ferences between regions in demographic variables, be-
cause these were controlled for in all the analyses. In par-
allel, the results could not have been an artifact of arbi-
trary categorization procedures across centers (which 
could otherwise explain the association between  APOE 
  4 and MCI subgroup), because the same pattern was also 
found for continuous measures (i.e. association between 
 APOE   4 and neuropsychological tests). To investigate 
 Regional Differences in Effects of  APOE 
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Dement Geriatr Cogn Disord 2011;32:135–142 141
other threats to the conclusions, we ran a number of post 
hoc analyses. First, two centers used ICD-10 for diagno-
sis, instead of DSM-IV as the rest. For that reason, analy-
ses were made when excluding those centers. This did not 
change the results. Further, it is possible that the present 
results could be explained by selection bias. For that rea-
son, differences in referral source were analyzed across 
regions. This showed an increasing north-south gradient 
in self-referral (north = 4.8%; middle = 9%; south = 33%; 
p = 0.001). However, after exclusion of self-referrals, re-
sults were essentially the same. Still, a specific referral 
pattern to a memory clinic could not be excluded. Final-
ly, the results could also have been an artifact of the clas-
sification of centers in geographical regions (which was 
made according to Corbo and Scacchi  [10] ). One concern 
regarding this is that the Bucharest center was included 
in the region of Southern Europe, although this center is 
really located in Eastern Europe. However, post hoc anal-
yses after exclusion of this centre from the southern re-
gion yielded similar results.
 However, there were also two limitations to the present 
study that were not addressed. First, a number of subjects 
were excluded from analyses due to missing data on ge-
notype or neuropsychological tests. There was a trend for 
these subjects to have a better performance on memory 
tests and higher level of education in some regions. Sec-
ond, the centers did not all use the same neuropsycho-
logical tests or norms. Differences in these procedures 
could have confounded the results. Future studies should 
consider using the same neuropsychological tests and 
norms in all regions. 
 In conclusion, geographical location was strongly as-
sociated with the frequency of  APOE   4 across Europe 
and modulated the relationship between the  APOE   4 al-
lele and cognition. For this reason, region-specific cut-
offs may be needed to define what could be considered to 
be a deviation from the reference  APOE   4 allele frequen-
cy. Future studies should focus on interactions of lifestyle 
or other genetic factors with the  APOE   4 allele that could 
account for the regional differences in the relation be-
tween  APOE genotype and cognitive impairment. Longi-
tudinal studies are also needed to see whether the rate of 
decline or the conversion from different MCI subtypes to 
different forms of dementia also varies between regions. 
The high prevalence of  APOE   4 carriers in all diagnostic 
groups suggests that SCI, non-amnestic MCI and amnes-
tic MCI all have an increased risk for AD.
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